Skip to main content

Table 1 Demographic and diagnostic data

From: United States multicenter study of factors predicting the persistence of GH deficiency during the transition period between childhood and adulthood

 

GHD at retest (peak GH <5 μg/L)

Non-GHD at retest*

p values**

Variable

Organic n = 18 (M:9; F:9)

Idiopathic n = 20 (M:13; F:7)

Total n = 38 (M:22; F:16)

All patients n = 35 (M:20; F:15)

All: GHD vs. non-GHD

Idiopathic: GHD vs. non-GHD

n (%) patients with isolated GH deficiency

4 (22)

7 (35)

11 (29)

62 (89)

  

Age at diagnosis (yr)1

10.0 ± 2.2

4.5 ± 3.2

7.1 ± 3.9

10.5 ± 3.3

<0.001

<0.0001

10.6 (6.3, 13.7)

4.6 (0.1, 11.6)

7.2 (0.1, 13.7)

11.0 (2.2, 16.9)

Age at retest (yr)

17.9 ± 2.2

17.6 ± 1.8

17.7 ± 2.0

17.0 ± 1.6

0.08

0.17

18.2 (14.1, 22.4)

17.6 (13.7, 21.9)

17.6 (13.7, 22.4)

16.7 (14.1, 20.2)

Duration of childhood GH treatment (yr) 1

5.6 ± 2.9

11.4 ± 3.6

8.6 ± 4.4

5.5 ± 2.8

<0.01

<0.0001

4.6 (2.0, 11.8)

12.2 (3.1, 16.7)

8.1 (2.0, 16.7)

4.7 (1.4, 12.7)

Time off GH (yr)

1.7 ± 1.6

1.5 ± 1.0

1.6 ± 1.3

0.9 ± 0.6

0.01

<0.01

1.2 (0.1, 5.0)

1.4 (0.2, 4.2)

1.3 (0.1, 5.0)

0.7 (0.2, 2.2)

Weight (kg)

76.9 ± 18.8

75.5 ± 19.7

76.2 ± 19.0

60.5 ± 10.0

<0.001

<0.01

74.6 (44.9, 119.3)

69.8 (47.1, 110.5)

74.2 (44.9, 119.3)

59.2 (42.5, 82.4)

BMI (kg/m2)

27.5 ± 6.2

26.4 ± 5.5

26.9 ± 5.8

21.9 ± 2.9

<0.001

<0.01

26.8 (15.1, 37.4)

26.2 (18.6, 37.4)

26.2 (15.1, 37.4)

21.0 (16.6, 29.8)

BMI SDS

0.9 ± 1.6

0.9 ± 1.2

0.9 ± 1.4

0.1 ± 0.9

<0.001

<0.01

1.4 (-4.4, 2.5)

1.4 (-1.8, 2.5)

1.4 (-4.4, 2.5)

0.2 (-2.3, 1.9)

Number of additional PHDs

2.3 ± 1.7

1.5 ± 1.4

1.9 ± 1.6

0.0 ± 0.2

<0.0001

<0.0001

2.5 (0.0, 4.0)

1.5 (0.0, 4.0)

2.0 (0.0, 4.0)

0.0 (0.0, 1.0)

Peak GH (μg/L)

0.7 ± 0.9

0.5 ± 0.6

0.6 ± 0.8

15.2 ± 10.1

<0.0001

<0.0001

0.2 (0.1, 3.0)

0.3 (0.0, 2.2)

0.2 (0.0, 3.0)

13.0 (5.0, 57.0)

IGF-I (μg/L)

100 ± 67

123 ± 78

112 ± 73

309 ± 123

<0.0001

<0.0001

86 (30, 265)

95 (20, 248)

93 (20, 265)

295 (117, 738)

IGF-I SDS

-6.2 ± 2.4

-5.7 ± 2.7

-6.0 ± 2.5

-1.9 ± 1.4

<0.0001

<0.0001

-6.0 (-9.8, –1.6)

-5.8 (-11.1, –1.6)

-5.8 (-11.1, –1.6)

-2.0 (-5.3, 1.5)

IGFBP-3 (μg/L)

2.5 ± 1.0

2.8 ± 1.3

2.7 ± 1.2

3.8 ± 0.7

<0.0001

<0.01

2.5 (1.1, 4.5)

2.4 (1.1, 5.9)

2.5 (1.1, 5.9)

3.8 (2.5, 5.4)

IGFBP-3 SDS

-1.4 ± 1.6

-1.2 ± 1.9

-1.3 ± 1.7

0.4 ± 0.8

<0.0001

<0.01

 

-1.3 (-4.5, 1.2)

-1.4 (-4.6, 2.4)

-1.3 (-4.6, 2.4)

0.4 (-1.2, 1.9)

  
  1. Values are means ± SD and median (minimum, maximum). *All patients who retested as non-GH deficient had idiopathic GH deficiency in childhood. **p values for comparisons of groups who were GH deficient vs. non-GH-deficient at retest were obtained from nonparametric Wilcoxon tests. 1Comparisons between organic vs. idiopathic patients with GHD at retest: p < 0.0001 for age at diagnosis and duration of childhood GH treatment; all others, nonsignificant.
  2. Abbreviations: BMI = body mass index, F = female, GH = growth hormone, GHD = GH deficiency, IGF-I = insulin-like growth factor I, IGFBP-3 = insulin-like growth factor binding protein 3, kg = kilogram, M = male, m2= meters squared, n = number, PHDs = pituitary hormone deficiencies, SDS = standard deviation score, yr = year.
Back to article page

International Journal of Pediatric Endocrinology

ISSN: 1687-9856

Contact us